# LoQus23 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/loqus23-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.loqus23.com/
- Total disclosed funding: $62M
- Latest round: Series A (Oct 2, 2024)
- Investors on record: 3

## About

LoQus23 Therapeutics, based in the UK, focuses on developing innovative small molecule somatic expansion inhibitors to combat Huntington's Disease and similar neurodegenerative disorders.Founded in 2019 in Cambridge, UK, LoQus23 Therapeutics specializes in the development of therapeutics for triplet repeat expansion diseases. The company has participated in 3 funding deals, with its most recent funding round being a Series A in October 2024, where it raised GBP 35 million, led by Forbion alongside Novartis Venture Fund and SV Health Investors. David Reynolds is the CEO of the company.LoQus23 Therapeutics specializes in the development of small molecule somatic expansion inhibitors aimed at treating Huntington’s Disease and other triplet repeat expansion diseases. The core product offerings focus on halting DNA instability, which contributes significantly to neurodegeneration. The primary end users are patients suffering from these disorders, along with healthcare providers and research institutions. The company's products are targeted towards markets in North America and Europe.In 2024, LoQus23 Therapeutics generated revenues of GBP 25,865.50 from its collaborations in the biopharmaceutical sector. The company engages in partnerships with research institutions and healthcare providers for the development of their proprietary inhibitors. The revenue model is closely tied to the successful validation and commercialization of its therapeutic products, including milestone payments and licensing agreements.LoQus23 Therapeutics plans to utilize the GBP 35 million raised in its most recent funding round to support pre-clinical development and initial clinical studies of a lead program focused on a small molecule MutSß inhibitor. The company aims to expand its therapeutic offerings and enter new markets, particularly in North America and Europe, by 2025.

## Funding rounds

- Series A, Oct 2, 2024, $47M — Novartis Venture Fund, SV Health Investors, Forbion
- Seed, Nov 19, 2021, $9.6M — Novartis Venture Fund, SV Health Investors
- Seed, Jan 1, 2019, $5.7M — SV Health Investors

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Seed, Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A